These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

68 related items for PubMed ID: 9832306

  • 1. Properties of HIV envelope expressed in the presence of SPC3, an Env-derived peptide drug under phase II clinical trials.
    Barbouche R, Fenouillet E, Papandréou MJ, Kiény MP, Sabatier JM.
    J Pept Res; 1998 Oct; 52(4):283-8. PubMed ID: 9832306
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. An anti-human immunodeficiency virus multiple antigen peptide encompassing the cleavage region of the env precursor interferes with membrane fusion at a post-CD4 binding step.
    Barbouche R, Decroly E, Kieny MP, Fenouillet E.
    Virology; 2000 Jul 20; 273(1):169-77. PubMed ID: 10891419
    [Abstract] [Full Text] [Related]

  • 8. Ion channel activation by SPC3, a peptide derived from the HIV-1 gp120 V3 loop.
    Carlier E, Mabrouk K, Moulard M, Fajloun Z, Rochat H, De Waard M, Sabatier JM.
    J Pept Res; 2000 Dec 20; 56(6):427-37. PubMed ID: 11152302
    [Abstract] [Full Text] [Related]

  • 9. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
    Laakso MM, Lee FH, Haggarty B, Agrawal C, Nolan KM, Biscone M, Romano J, Jordan AP, Leslie GJ, Meissner EG, Su L, Hoxie JA, Doms RW.
    PLoS Pathog; 2007 Aug 24; 3(8):e117. PubMed ID: 17722977
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P, Earl PL, Sironi F, Santoro F, Ripamonti C, Scarlatti G, Longhi R, Berger EA, Burastero SE.
    J Virol; 2005 Jun 24; 79(11):6957-68. PubMed ID: 15890935
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Biological properties of recombinant HIV envelope synthesized in CHO glycosylation-mutant cell lines.
    Fenouillet E, Miquelis R, Drillien R.
    Virology; 1996 Apr 01; 218(1):224-31. PubMed ID: 8615025
    [Abstract] [Full Text] [Related]

  • 17. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC, Stuber G, Wagner R, Wolf H, Modrow S.
    J Pept Sci; 1995 Apr 01; 1(2):109-23. PubMed ID: 9222988
    [Abstract] [Full Text] [Related]

  • 18. SPC3, a nontoxic peptide inhibitor of HIV infection.
    Sabatier JM, Baghdiguian S, Yahi N, Rochat H, Van Rietschoten J, Fantini J.
    In Vitro Cell Dev Biol Anim; 1995 Jun 01; 31(6):415-8. PubMed ID: 8589880
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.